TipRanks (Thu, 4-Jun 2:00 AM ET)
Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results
Globe Newswire (Wed, 27-May 8:00 AM ET)
Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026
Globe Newswire (Tue, 5-May 1:39 PM ET)
MESA LABS DECLARES QUARTERLY DIVIDEND
Globe Newswire (Thu, 2-Apr 6:00 PM ET)
Mesa Laboratories Announces CEO Transition and Appointment of Siddhartha Kadia as President and CEO
Globe Newswire (Mon, 9-Mar 4:30 PM ET)
Upcoming Q3 Results Could Shift Outlook for MLAB—What to Watch Ahead of February 3 Announcement
Market Chameleon (Thu, 4-Dec 5:45 AM ET)
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
Mesa Laboratories trades on the NASDAQ stock market under the symbol MLAB.
As of June 8, 2026, MLAB stock price climbed to $108.46 with 178,877 million shares trading.
MLAB has a beta of 1.59, meaning it tends to be more sensitive to market movements. MLAB has a correlation of 0.10 to the broad based SPY ETF.
MLAB has a market cap of $599.22 million. This is considered a Small Cap stock.
Last quarter Mesa Laboratories reported $64 million in Revenue and $3.30 earnings per share. This fell short of revenue expectation by $-1 million and exceeded earnings estimates by $1.83.
In the last 3 years, MLAB traded as high as $155.12 and as low as $55.45.
The top ETF exchange traded funds that MLAB belongs to (by Net Assets): VTI, IWM, VXF, IWO, FESM.
MLAB has underperformed the market in the last year with a return of +9.3%, while SPY returned +25.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in MLAB shares. However, MLAB has outperformed the market in the last 3 month and 2 week periods, returning +24.0% and 0.0%, while SPY returned +8.8% and -0.9%, respectively. This indicates MLAB has been having a stronger performance recently.
MLAB support price is $99.99 and resistance is $107.79 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MLAB shares will trade within this expected range on the day.